Search

In Stock

Buy Kalydeco (ivacaftor) Online

DISEASE INDICATIONS: Cystic Fibrosis

MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd

USAGE: Oral

MEDICINE APPROVED BY:

European Medical Agency (EMA)

Food and Drug Administration (FDA)

Kalydeco (ivacaftor) is a medication prescribed for individuals with cystic fibrosis (CF) who are 4 months of age and older and possess at least one CF gene mutation that responds to Kalydeco treatment.

From $7,241.59

Clear
Compare

What is Kalydeco (ivacaftor) used for?
Kalydeco (ivacaftor) is intended for patients aged 4 months and older who have cystic fibrosis (CF) and possess at least one mutation in their CF gene that responds to Kalydeco. It is available in tablet form, with each tablet containing 150 mg of ivacaftor.

How does Kalydeco (ivacaftor) work?
Cystic Fibrosis (CF) is a severe genetic disorder characterized by the accumulation of thick mucus in the lungs, digestive tract, and other body parts. This leads to significant respiratory and digestive problems, as well as complications such as infections and diabetes. Mutations in the CFTR gene are responsible for CF. This gene encodes a protein known as ‘cystic-fibrosis transmembrane conductance regulator’ (CFTR), which plays a role in regulating mucus and digestive juice production. These mutations either reduce the number of CFTR protein channels on cell surfaces or disrupt their functioning. These channels are vital for transporting ions (charged atoms and molecules) in and out of cells. When these channels are defective, mucus and digestive juices can become excessively thick and sticky.

Kalydeco (ivacaftor) enhances the activity of impaired CFTR proteins, facilitating ion transport. This action helps reduce CF symptoms by making mucus and digestive juice less thick.

Where has Kalydeco (ivacaftor) been approved?
Kalydeco (ivacaftor) has been approved for the treatment of CF patients with CFTR gene mutations by:

– The Food and Drug Administration (FDA) in the USA on January 31, 2012.
– The European Medical Agency (EMA) in the European Union on August 6, 2012.

Please note that this medication may have received approval in regions beyond the ones mentioned. If you have inquiries about its approval in a specific country, please feel free to contact our support team.

How is Kalydeco (ivacaftor) administered?
The standard dosage for Kalydeco (ivacaftor) is as follows:

For use as monotherapy in patients older than 4 months:
– Taken orally twice a day.
– One tablet should be taken every 12 hours with food containing fat.

In combination with tezacaftor/ivacaftor for adults and adolescents aged 6 and older:
– Taken orally once a day.
– One tezacaftor 100 mg/ivacaftor 150 mg tablet is taken orally in the morning, and one Kalydeco (ivacaftor) tablet is taken in the evening approximately 12 hours apart with food containing fat.

The dose of Kalydeco (ivacaftor) should be adjusted for:

– One 150 mg ivacaftor tablet once daily for patients with moderate hepatic impairment.
– One 150 mg ivacaftor tablet every other day for patients with severe hepatic impairment. Dosing intervals should be adapted based on clinical response and tolerability.

The dose of Kalydeco (ivacaftor) must be modified to:

– One tablet twice a week when co-administered with strong CYP3A inhibitors.
– One tablet once daily when co-administered with moderate CYP3A inhibitors.

For complete information about Kalydeco (ivacaftor) dosage and administration, please refer to the official prescribing information listed in our resources section.

Note: Consult with your treating doctor for personalized dosing and potential drug interactions.

Are there any known side effects or adverse reactions to Kalydeco (ivacaftor)?
Common adverse reactions listed in the prescribing information include:

– Upper respiratory tract infection
– Nasopharyngitis (contagious throat disease)
– Headache
– Dizziness
– Oropharyngeal pain
– Nasal congestion
– Abdominal pain
– Diarrhea
– Elevated liver enzymes
– Rash
– Presence of bacteria in mucus.

Package

28 tablets of 150 mg, 56 tablets of 75 mg, 56 tablets of 150 mg, 56 tablets of 75 mg, 56 tablets of 50 mg, 56 granule sachets of 25 mg, 56 granule sachets of 50 mg, 56 granule sachets of 75 mg

Reviews

There are no reviews yet.

Write a review

Your email address will not be published. Required fields are marked *

Bestsellers

Buy Tezspire (tezepelumab-ekko) Online

$6,696.25
(0 Reviews)
DISEASE INDICATIONS: Asthma MANUFACTURER: Amgen / AstraZeneca AB USAGE: Subcutaneous MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Tezspire (tezepelumab-ekko) is a prescription medication that belongs to the drug class of monoclonal antibodies. It is used to treat severe asthma in adults and children 12 years of age and older whose condition cannot be managed by their existing asthma medication. Tezspire is the first and only biologic approved for severe asthma without phenotypic or biomarker limitations.

Buy Trikafta (elexacaftor/tezacaftor/ivacaftor; ivacaftor) Online

From $39,106.10
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals Incorporated USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA)   Trikafta is designed to address the underlying genetic mutations in individuals with CF and has been shown to significantly improve lung function and overall health in many patients.

Buy Orkambi (lumacaftor/ivacaftor) Online

From $10,806.14
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Therapeutic Goods Administration (TGA) This medication is designed to address the underlying cause of CF in individuals who have two copies of the F508del mutation in the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) gene, which is a common genetic mutation associated with CF.

Buy Symdeko (tezacaftor / ivacaftor) Online

$39,418.95
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) , Symdeko is indicated for the treatment of patients with CF who have specific genetic mutations that are responsive to these medications. This combination therapy addresses the underlying cause of CF by improving the function of the CFTR (Cystic Fibrosis Transmembrane Conductance Regulator) protein, which is often dysfunctional in CF patients.

Buy Kalydeco (ivacaftor) Online

From $7,241.59
(0 Reviews)
DISEASE INDICATIONS: Cystic Fibrosis MANUFACTURER: Vertex Pharmaceuticals (Europe) Ltd USAGE: Oral MEDICINE APPROVED BY: European Medical Agency (EMA) Food and Drug Administration (FDA) Kalydeco (ivacaftor) is a medication prescribed for individuals with cystic fibrosis (CF) who are 4 months of age and older and possess at least one CF gene mutation that responds to Kalydeco treatment.

Buy Clenbuterol Harasawa Online

$102.85
(0 Reviews)
DISEASE INDICATIONS: Amyotrophic Lateral Sclerosis (ALS) MANUFACTURER: Harasawa USAGE: Oral MEDICINE APPROVED BY: Pharmaceuticals and Medical Devices Agency (PMDA) Clenbuterol, a medication employed in the management of individuals afflicted with bronchial asthma, chronic bronchitis, emphysema, acute bronchitis, or stress urinary incontinence, has diverse applications in the medical field. Notably, physicians occasionally opt for Clenbuterol's off-label use in the treatment of patients grappling with ALS (Amyotrophic Lateral Sclerosis). It's worth mentioning that Clenbuterol was previously recognized by its brand name, TONIL (clenbuterol).

Buy Breztri Aerosphere (budesonide/glycopyrrolate/formoterol fumarate) Online

$305.35
(0 Reviews)
DISEASE INDICATIONS: Chronic Obstructive Pulmonary Disease MANUFACTURER: AstraZeneca Pharmaceuticals LP USAGE: Oral MEDICINE APPROVED BY: Food and Drug Administration (FDA) Pharmaceuticals and Medical Devices Agency (PMDA)   Breztri Aerosphere is a pharmaceutical medication that is primarily used for the treatment of chronic obstructive pulmonary disease (COPD). This medication is designed to provide relief and management of the symptoms associated with COPD, which includes chronic bronchitis and emphysema.

Back to Top
Product has been added to your cart